ESR1 and breast cancer: Since the overexpression of DSCAM-AS1 was observed not only in ERα+ but also in HER2+ breast tumors, we investigated the effects of DSCAM-AS1 knockdown in the SK-BR-3 cell line, a commonly used HER2+ BC cell model.